Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07174622

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location status: Recruiting

Location contact

Eric A. Secemsky, MD, MSc

CONTACT

[email protected]

617-632-7753

About this study

The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrolled in a Medicare plan
  • Diagnosis of uncontrolled hypertension
  • On a stable regimen of antihypertensive therapy

Exclusion criteria

  • A prior RDN procedure
  • Diagnosis of secondary hypertension
  • Any condition for which RDN is contraindicated

Treatment and study plan

Renal Denervation (Symplicity Spyral™)

Device

Symplicity Spyral™ multi-electrode renal denervation system

Primary outcomes

  1. Change in Office Systolic Blood Pressure (OSBP)

    Time frame: 2 years

    Change in OSBP at two years relative to baseline between matched treated and comparator cohorts.

Secondary outcomes

  1. Time to Major Cardiovascular Event (MACE)

    Time frame: 2 years

    The secondary outcome is time to MACE over 2 years for the matched treated and comparator cohorts. MACE is defined as the composite of non-fatal stroke, non-fatal myocardial infarction, and all-cause death.

Study contacts

Contact information is provided by the study sponsor or research team.

Kael Wherry, PhD, MS

CONTACT

[email protected]

612-229-0714

Sponsors and collaborators

Lead sponsor

Medtronic Vascular

Industry

Registry information

Official study title

Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data

Acronym: SPYRAL CARE

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Sep 16, 2025
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.